title: Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
abstract: BACKGROUND
  Nighttime agitation occurs frequently in patients with dementia and represents the number one burden on caregivers today. Current treatment options are few and limited due to substantial side effects.
  
  
  OBJECTIVE
  The aim of the study was to measure the effect of the cannabinoid dronabinol on nocturnal motor activity.
  
  
  METHODS
  In an open-label pilot study, six consecutive patients in the late stages of dementia and suffering from circadian and behavioral disturbances-five patients with Alzheimer's disease and one patient with vascular dementia-were treated with 2.5 mg dronabinol daily for 2 weeks. Motor activity was measured objectively using actigraphy.
  
  
  RESULTS
  Compared to baseline, dronabinol led to a reduction in nocturnal motor activity (P=0.028). These findings were corroborated by improvements in Neuropsychiatric Inventory total score (P=0.027) as well as in subscores for agitation, aberrant motor, and nighttime behaviors (P<0.05). No side effects were observed.
  
  
  CONCLUSIONS
  The study suggests that dronabinol was able to reduce nocturnal motor activity and agitation in severely demented patients. Thus, it appears that dronabinol may be a safe new treatment option for behavioral and circadian disturbances in dementia.
authors.affiliation: Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Charité Mitte (PUK), Berlin, Germany. sebastian.walther@gef.be.ch
authors.forename: Sebastian
authors.initials: S
authors.lastname: Walther
authors.forename: Richard
authors.initials: R
authors.lastname: Mahlberg
authors.forename: Uta
authors.initials: U
authors.lastname: Eichmann
authors.forename: Dieter
authors.initials: D
authors.lastname: Kunz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications / Q000523:psychology; D003704:Dementia / Q000150:complications* / Q000523:psychology; D015140:Dementia, Vascular / Q000150:complications / Q000523:psychology; D013759:Dronabinol / Q000009:adverse effects / Q000627:therapeutic use*; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006213:Hallucinogens / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010865:Pilot Projects; D011595:Psychomotor Agitation / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D012893:Sleep Wake Disorders / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology
chemical_list: D006213:Hallucinogens; D013759:Dronabinol